ミノサイクリン·塩酸塩 化学特性,用途語,生産方法
外観
うすい黄色～褐黄色、結晶～粉末
溶解性
メタノールにやや溶けやすく、水にやや溶けにくい。
用途
テトラサイクリン系抗生物質
です。細菌の 30S リボソームに結合し、ア
ミノアシル -tRNA のリボソーム上の A 部位
への結合を阻害します。抗菌スペクトルは広
く、マイコプラズマ、クラミジアなどにも抗
菌作用を示します。
用途
テトラサイクリン系抗生物質
です。細菌の 30S リボソームに結合し、ア
ミノアシル -tRNA のリボソーム上の A 部位
への結合を阻害作用を示します。抗菌スペク
トルは広く、マイコプラズマ、クラミジア等
にも抗菌作用を示します。
効能
抗生物質, タンパク質合成阻害薬
商品名
ペリオクリン (サンスター); ミノサイクリン塩酸塩 (沢井製薬); ミノマイシン (ファイザー); ミノマイシン (ファイザー); ミノマイシン (ファイザー); ミノマイシン (ファイザー)
化学的特性
Yellow Crystalline Powder
使用
Minocycline hydrochloride is a salt prepared from minocycline, taking advantage of the two basic dimethylamino groups which protonate and readily form a salt from hydrochloric acid solutions. The hydrochloride is the preferred formulation for pharmaceutical applications. Like all tetracyclines, minocycline shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal sub-units, blocking protein synthesis.
一般的な説明
Minocycline, 7-dimethylamino-6-demethyl-6-deoxytetracycline(Minocin, Vectrin), the most potent tetracycline currentlyused in therapy, is obtained by reductive methylationof 7-nitro-6-demethyl-6-deoxytetracycline. It was releasedfor use in the United States in 1971. Because minocycline,like doxycycline, lacks the 6-hydroxyl group, it is stablein acids and does not dehydrate or rearrange to anhydroor lactone forms. Minocycline is well absorbed orally togive high plasma and tissue levels. It has a very long serumhalf-life, resulting from slow urinary excretion and moderateprotein binding. Doxycycline and minocycline, alongwith oxytetracycline, show the least in vitro calcium bindingof the clinically available tetracyclines. The improved distributionproperties of the 6-deoxytetracyclines have been attributedto greater lipid solubility.
Perhaps the most outstanding property of minocyclineis its activity toward Gram-positive bacteria, especiallystaphylococci and streptococci. In fact, minocycline hasbeen effective against staphylococcal strains that are resistantto methicillin and all other tetracyclines, includingdoxycycline. Although it is doubtful that minocyclinewill replace bactericidal agents for the treatment of lifethreateningstaphylococcal infections, it may become auseful alternative for the treatment of less serious tissueinfections. Minocycline has been recommended for thetreatment of chronic bronchitis and other upper respiratorytract infections. Despite its relatively low renal clearance,partially compensated for by high serum and tissuelevels, it has been recommended for the treatment of urinary tract infections. It has been effective in the eradicationof N. meningitidis in asymptomatic carriers.
副作用
Common side effects of Minocycline hydrochloride include: nausea, vomiting, diarrhoea, dizziness, lightheadedness or spinning sensation. Individuals may experience symptoms of serious adverse reactions such as gingival hyperpigmentation, pain/difficulty swallowing, tinnitus or hearing loss, joint stiffness/pain/swelling, nephrotoxicity (elevated urea nitrogen, interstitial nephritis), hepatotoxicity (hyperbilirubinaemia, hepatic cholestasis, elevated liver enzymes, fatal hepatic failure, and jaundice), and hypersensitivity reactions. It rarely causes elevated pressure around the brain (intracranial hypertension - IH). The risk of this side effect is greater in women of childbearing age who are overweight or who have had IH in the past. Serious intestinal disorders including: non-stop diarrhoea, abdominal or stomach pain/cramps, and blood/mucus in the stool are less common.
ミノサイクリン·塩酸塩 上流と下流の製品情報
原材料
準備製品